You are here


Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R42CA281356-01
Agency Tracking Number: R42CA281356
Amount: $327,767.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: 102
Solicitation Number: CA22-017
Solicitation Year: 2022
Award Year: 2023
Award Start Date (Proposal Award Date): 2023-08-01
Award End Date (Contract End Date): 2024-07-31
Small Business Information
Irvington, NY 10533-1917
United States
DUNS: 118245366
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: Yes
Principal Investigator
 (813) 766-7280
Business Contact
Phone: (813) 766-7280
Research Institution
NEW YORK, NY 10019-5905
United States

 Nonprofit College or University

Project Summary/Abstract
Although cancer is a leading cause of death globally, oncology drugs have the lowest success rates, cost the
most to develop, and constantly show promising results in animals and then fail to work in patients. Thus, there
is a need for models that facilitate understanding of how a drug will work in humans and for specific patient
populations. The availability of human tumor samples will further facilitate enhanced preclinical screening, where
long timelines (rt10 years), high costs ($2.6B), and low success rates (1/5,000) plague the development of new
drugs. Link Biosystems provides a universal approach to tumor cell expansion via a custom bioreactor product
that uses a defined serum-free media and relies on controlled aggregation for enhanced paracrine signaling and
cell-cell contact, enhanced nutrient delivery via low-shear perfusion, and organotypic tissue niches to generate
thousands of identical immunocompetent tumoroid tissues that can be further scaled as needed. This approach
would enable the establishment of robust tumor models for early and late stage cancers, rare cancers, and
previously biobanked samples at quantities suitable for screening large drug panels – including
immunotherapies, biologics, and drug-drug combinations, to find an optimally effective drug regimen for the
specific patient. Additionally, the ability to generate quality-controlled patient cells at scale will enable the
establishment of patient tumor biobanks and subsequent personalized drug screening for optimal treatment
guidance and to overcome drug resistant phenotypes. To this end, we are similarly evaluating our bioreactors
versatile utility for expansion of direct patient tumor samples and previously biobanked organoid models,
providing the raw material needed for downstream drug screening assays that are human, robust, reproducible,
incorporates immune and stromal components, and captures the heterogeneity of patient responses.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government